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Abstract: A set of nicotinic acid derived tetrazines were 
synthesized and evaluated for activity in inverse electron 
demand Diels-Alder (IEDDA) reactions with various 
dienophiles. It was found that the performance of these tetrazines 
is governed by two factors. Theoretical and experimental 
investigations showed that steric effects may override the 
energetically predicted order of reactivity. Making a 
compromise between reactivity and stability a selected tetrazine 
was incorporated into a deoxynucleotide to afford a 
bioorthogonalized bulding block enabling IEDDA based tagging 
schemes of nucleic acids. 
Key words: tetrazine, inverse electron demand Diels-Alder, 
bioorthogonal, nucleic acid, labeling  
Chemical manipulation, e.g. fluorescent tagging of 
biomolecules by means of inverse electron demand 
Diels-Alder (IEDDA) reaction between tetrazines and 
strained ring systems present the fastest bioorthogonal 
modulation procedure today.1 Accordingly, selective 
and efficient labelling of DNA2,3 and RNA4 was 
achieved by activated olefins as building blocks, 
introduced either as phosphoramidites or nucleoside 
triphosphates. Most recently, it was shown that this 
type of DNA modification chemistry works also in 
living cells.3 Orthogonality of such IEDDA reactions 
with other bioorthogonal transformations for example, 
with strain promoted azide-alkyne cycloaddition 
(SPAAC) was also examined.5 In fact, one-pot dual 
labeling by IEDDA and copper-catalyzed cycloaddition 
was already realized for modification of DNA.6 
Orthogonal modification of biomatter by the same 
bioorthogonal transformation is also possible. Lemke 
and co-workers demonstrated that tetrazines with 
distinct reactivities towards dienophiles enable pulse-
chase labeling of insulin receptors expressing non-
canonical amino acids that harbor different 
dienophiles.5 In this latter report the distinct reactivity 
of a non-symmetrically and a mono-substituted 
tetrazine implies the governing effects of the steric 
demand of the substituents in the proximity of the 
reaction center.  
For our purposes that involve the development of 
bioorthogonalized oligonucleotides we have sought for 
new tetrazine derivatives with reasonable reactivities 
and stability suitable for longer in vivo exposure. 
Reactivity and stability are two seemingly 
contradictory properties, and in most cases a 
compromise is necessary when selecting 
biorthogonally applicable reagents. Former examples 
show that the reactivity of tetrazines can be predicted 
with relatively high fidelity as it is mainly governed by 
the energy of its frontier molecular orbital (LUMO).7 
As a rule of thumb, electron withdrawing substituents 
lower the energy of the LUMO of the tetrazine scaffold 
therefore increase reactivity.7  
The presence of pyridine units appending from the 
tetrazine core is often beneficial for the reactivity of 
tetrazines towards dienophiles.1,7 For its synthetic 
accessibility, further functionalization and its rate 
enhancing features, we have chosen nicotinic acid 
based nitriles to build up activated tetrazine scaffolds. 
We were also curious of inspecting the effect of steric 
demand of the substituents on the reaction rate. 
Therefore we have designed three nicotinic amide 
modified tetrazines as model compounds in order to 
evaluate their reactivity towards selected dienophiles 
(Figure 1).  
 
Figure 1 Structure of model tetrazines with different steric demand 
(top) and dienophiles used in this study (bottom). 
The synthesis of monosubstituted tetrazine (1) started 
with the reaction of 6-cyano-N,N-diethylnicotinamide 
(5) with aqueous hydrazine in the presence of 
formamidine acetate. The resulting dihydrotetrazine 
was oxidized directly with isopentyl-nitrite to furnish 1 
in 42% yield (2 steps). Non-symmetrically substituted 
tetrazine (2) was made in a similar manner from 5 and 
acetonitrile in the presence of hydrazine-hydrate. The 
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primary product dihydrotetrazine was treated with in 
situ generated nitrous gases to provide 2 in an overall 
10% yield. Symmetrically decorated tetrazine (3) was 
obtained by treating 6-cyano-N,N-diethylnicotinamide 
with hydrazine-hydrate. Subsequent oxidation with 
nitrous gases yielded 3 in an overall 30% yield (Scheme 
1).  
 
Scheme 1 Synthesis of model tetrazines. a) HNEt2, HOBt, HBTU, 
DIPEA, THF, r.t. 16h, 87%; b) N2H4.H2O, THF, , 16h; c) [NOx], 
CH2Cl2, r.t. 15 min, 30% (3), 10% (2) (2 steps); d) formamidine 
acetate, N2H4.H2O, EtOH, , 16h; e) isopentyl nitrite, CH2Cl2, r.t. 
3h, 42%; f) N2H4.H2O, MeCN, , 16h . 
With these model compounds in hand we were curious 
how these tetrazines react with simple, sterically less 
demanding - and less reactive - dienophiles like ethyl-
vinyl ether (EVE). For comparison, we have used 
dipyridyl tetrazine (DPT)8 as standard. In order to 
mimic intracellular conditions, the reactions were 
accomplished under pseudo-first order conditions. 
Evaluation of the results showed that symmetrically 
substituted 3 and monosubstituted 1 react with EVE at 
comparable speeds (k2 = 8 and 24 ×10-3 M-1s-1, 
respectively), while compound 2 and DPT gave k2 
values an order of magnitude lower. It should be noted 
that this order of rate constants is not in line with the 
reactivity order predicted by the LUMO energies 
(Table 1) and confirms our belief that steric demand of 
the substituents can also contribute to the overall 
reactivity.  
To track down the effects of steric demand we have 
conducted another series of experiments where 
tetrazines 1 and 3 were reacted with a more reactive but 
bulkier dienophile (CyO)9. In this case the difference 
in rate constants was even more profound. 
Monosubstituted 1 reacted ca. 30 times faster than 
energetically favored symmetrical tetrazine 3. 
Table 1 Second order rate constants of the reaction between 
tetrazines and various dienophiles. The LUMO energies were 
calculated at the Hartree–Fock level of theory with the 6-311++G** 
basis set at B3LYP/6-311++G** geometries   
tetrazine t1/2 LUMO k2 / M-1s-1 
(h) (eV) EVEa CyOa COMBOb TCOb 
       
DPT 310 0.28 0.0012 --- --- --- 
1 4 0.71 0.024 6.25 --- --- 
2 88 0.83 0.00145 --- 210 4000 
3 4 0.46 0.008 0.23 --- --- 
4 6 0.69 0.010 2.89 --- --- 
a) measured in DMSO/water (9/1 v/v) at 25 °C; b) measured in 1% 
DMSO in PBS buffer (pH 7.2) at 36 °C. 
To verify our findings we have also run theoretical 
calculations involving steric demand of reactants in 
transition states for the selected reactions. The 
geometries of the tetrazines and dienophiles as well as 
the corresponding transition states were optimized at 
the density functional (DFT) level using the B3LYP 
(Becke 3-parameter Lee-Yang-Parr exchange-
correlation) functional11 and the 6-311++G** basis set. 
To save computer time the ethyl groups of the tetrazine 
derivatives were replaced by methyl groups. For each 
molecule considered, several stable conformers exist, 
which slightly differ in energy. The geometry of all 
conformers was optimized, and the lowest-energy one 
was considered in the subsequent transition state 
searches.  
Table 2 Gibbs energies of activation (ΔG‡, kcal/mol) for the 
reactions of tetrazines 1 and 3 with ethyl-vinyl ether and CyO 
evaluated at the B3LYP level with the 6-311++G** basis set  
Tetrazine Ethyl-vinyl ether CyO 
1 31.5 24.4 
   
3 33.4 29.4 
   
Furthermore, except for the reaction of 3 with EVE 
several transition state structures can be located. We 
determined the activation barriers for all the possible 
structures, but only the transition states with the lowest 
barriers are considered here. At the optimized 
geometries harmonic vibrational frequencies were 
evaluated and Gibbs energies of activation were 
computed in the rigid rotor-harmonic oscillator 
approximation. All calculations were carried out with 
the Gaussian 09 suite of quantum chemistry 
programs12. 
The results are compiled in Table 2, while in Figure 2 
the transition-state geometries are visualized for the 
reactions of 1 and 3 with CyO. To our delight, data are 
in good correlations with the experimental results. The 
free energies of activation are higher for compound 3 
with both dienophiles. In addition, the difference 
between the activation barriers for the reactions of 1 
and 3 is somewhat bigger for CyO. As can be seen in 
Figure 2 the methyl group of CyO is rather close to the 
hydrogen atom at the pyridine substitutent. Thus the 
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steric repulsion is considerably stronger between the 
derivative substituted with the bulky pyridine group 
and CyO, which explains the observed behavior of the 
compounds. 
 
Figure 2 Optimized transition-state structures for the 1 + CyO (top) 
and the 3 + CyO (bottom) reactions. 
Next we have examined the stability of the tetrazines 
by determining their half-lives in aqueous solutions 
(pH 7.2 PBS). As expected, the stability was found to 
be inversely proportional to reactivity. Whilst 1 reacted 
the fastest with all dienophiles it decomposed in 
aqueous solutions relatively rapidly. Tetrazine 2 on the 
other hand was found to be quite stable under similar 
conditions. 
We have attempted to preserve reactivity in a more 
stable tetrazine scaffold. Thus we have synthesized 
tetrazine derivative 4 (see supporting information). We 
have anticipated that compound 4 would be more stable 
yet with comparable in reactivity to 1. The synthesis of 
4 was accomplished similarly to that of 1. Acetylation 
of 5-aminopicolinonitrile with acetyl chloride and 
subsequent reaction with formamidine acetate in the 
presence of hydrazine hydrate followed by oxidation 
with isopentyl nitrite provided model tetrazine 4 in 
medium yields (see supporting information). While the 
second order rate constant of 4 was determined to be as 
expected its stability turned out to be only slightly 
better than 1.  
Our continuing efforts on DNA modification studies13 
require bioorthogonal handles stable enough to survive 
solid phase oligonucleotide synthesis (SPOS) or stand 
in vivo conditions. Thus, we have sacrificed reactivity 
for stability and chose tetrazine 2 for further studies. To 
judge the reactivity of 2 we have conducted kinetic 
studies in the presence of highly strained and reactive 
dienophiles. To our delight, monobenzocyclooctyne 
(COMBO)14 and trans-cyclooctene (TCO)15 reacted 
quite rapidly with 2 (Table 1) justifying its use in 
reasonably fast bioorthogonal labeling schemes. The 
reactivity of 2 with COMBO is in good accordance 
with similar studies with a structurally related 
derivative of 2 with another, less reactive strained 
cyclooctyne BCN16 (k2(COMBO) = 210 M-1s-1 vs. k2(BCN) 
= 80 M-1s-1).17 
Next, we aimed at incorporating non-symmetrically 
substituted tetrazine 2 into a deoxyuridine-
phosphoramidite building block. It bears the tetrazine 
unit linked by an aminopropynyl group at the 5-
position. This has two advantages: Firstly, it potentially 
allows to use this nucleoside conjugate for primer 
extension and PCR since commonly applied DNA 
polymerases like KlenTaq polymerase typically 
tolerate such modifications.18 Secondly, the structural 
influence by this modification should be rather small. 
For this, we treated cyanonicotinic acid with hydrazine 
hydrate in the presence of triethyl orthoacetate 
(Scheme 2). Subsequent oxidation with NaNO2 / HCl 
furnished tetrazine 6. Parallel to this, commercially 
available 5-iodo-2’-deoxyuridine was subjected to a 
Sonogashira-type coupling reaction with 
trifluoroacetate protected propargylamine.13,19 After 
removal of the protecting group in aqueous ammonia 
the resulting amino functionalized 2’-deoxyuridine was 
reacted with 6 in the presence of HBTU / HOBt and 
Hünig’s base. The tetrazine modified 2’-deoxyuridine 
7 was converted to its phosphoramidite using 
2-cyanoethyl-N,N-diisopropylchlorophosphoramidite 
to furnish phosphoramidite 8 (Scheme 2).  
Tetrazine modified 2’-deoxyuridine phosphoramidite 
(8) was incorporated into a model oligonucleic acid 
DNA1 using standard SPOS methods. The synthetic 
protocol was modified such that the removal of the last 
DMT-protecting group from the complete sequence 
was followed by an automated on-bead labeling step 
applying a reactive cyclooctyne derivatized fluorescein 
dye (COMBO-Flu, Figure 3)14 for 60 s. Mass 
spectrometry of the labeled oligonucleotide verified the 
existence of the right product. Spectrophotometric 
analysis of the labeled DNA showed the characteristic 
absorption and emission bands of fluorescein at around 
500 and 520 nm, respectively. Upon hybridization of 
the labeled strand with its complementary strand, 
DNA1c, an increase of extinction, especially of the 
band at 500 nm, could be observed (see supporting 
information). This increase can be explained by 
unshielding the dye from the DNA bases upon 
annealing the randomly folded single stranded DNA.13 
Formation of a structured double-stranded DNA 
presumably forced the fluorescein moiety outside the 
DNA-helix and face towards the more polar aqueous 
environment. This is supported by the melting 
temperatures that show only a slight decrease relative 
to that of the unmodified DNA (56.8 °C vs. 59.5 °C). 
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Scheme 2 Synthesis of bioorthogonalized 2’deoxyuridine-phosphoramidite 8. a) triethyl orthoacetate, N2H4×H2O, , 2h; b) NOx, CH2Cl2, rt., 3h, 
25% (for 2 steps). c) DMT-dU-propargylamine, HBTU, HOBt, DIPEA, DMF, 16h, 65% d) 2-cyanoethyl-N,N-diisopropylchloro phosphoramidite, 
DIPEA, CH2Cl2, 89%.
An on-bead labeling typically does not allow to 
determine yields of coupling efficiencies. However, the 
incorporation efficiency of the tetrazine modified 
building block was comparable to that of the 
commercial building blocks for A, G, T and C. 
 
Figure 3 Sequence of DNA1 with the tetrazine building block 8 that 
reacts rapidly with the cycloocytyne-modified fluoresceine 
(COMBO-Flu). 
This study revealed that steric demand of substituents 
play prominent role in the Diels-Alder reactivity of 
electron deficient tetrazines. We have investigated the 
reaction rates of model tetrazines in the presence of 
various dienophiles. The experimental findings were 
supported by theoretical investigations as well. Besides 
reactivity, the stability of these new tetrazines was also 
studied and it was found that only the least reactive, 
non-symmetrically decorated tetrazine can stand 
physiological conditions for longer times. For our 
purposes, we therefore used this scaffold in the design 
of a bioorthogonalized nucleic acid building block, 8. 
Incorporation of this modified building block into a 
DNA sequence using standard solid phase nucleic acid 
synthesis, a fully automated protocol together with 
subsequent on-bead labeling experiment revealed that 
this tetrazine is suitable for the implementation of a 
reactive bioorthogonal handle into oligonucleotides.  
Though in this study we have sought for stable 
tetrazines for incorporation into biomolecular building 
blocks, the more reactive tetrazines developed in this 
study can be used e.g. for labeling purposes where 
exposure times range only between 0.1 – 2 h. Related 
labeling studies with reactive tetrazines as well as 
attempts to synthesize a nucleotide-triphosphate 
derivative of 8 in order to test the suitability of this 
unnatural building block in PCR applications are in 
progress and results will be reported in due course.  
 
General:  
Unless otherwise indicated, all starting materials were 
obtained from commercial suppliers (Sigma-Aldrich, 
Fluka, Merck, Alfa Aesar, Reanal, Molar Chemicals) 
and used without further purification. Dichloromethane 
stabilized with ethanol was used, unless otherwise 
mentioned. CyO, COMBO and TCO were synthesized 
according to literature procedures.9,14,15 Analytical 
thin-layer chromatography (TLC) was performed on 
silica gel 60 F254 precoated aluminium TLC plates 
from Merck. Column chromatography was carried out 
with flash silica gel (0.040–0.063 mm) from Molar 
Chemicals. Visualization of TLC samples was 
performed with a 254/365 nm UV. NMR spectra were 
recorded on a Bruker Avance 250 MHz, Bruker Avance 
III 400 MHz or a Varian Inova 600 MHz spectrometer. 
Chemical shifts (δ) are given in parts per million (ppm) 
using solvent signals as the reference. Coupling 
constants (J) are reported in Hertz (Hz). Splitting 
patterns are designated as s (singlet), d (doublet), t 
(triplet), qr (quadruplet), qv (quintuplet), m (multiplet), 
dd (doublet of a doublet), td (triplet doublet), dt 
(doublet triplet), br s (broad singlet). The exact masses 
were determined with an Agilent 6230 time-of-flight 
mass spectrometer. All melting points were measured 
on a Bibby Scientific SMP10 Melting Point Apparatus 
and are uncorrected. IR spectra were obtained on a 
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Bruker Alpha-P spectrometer on a single-reflection 
diamond ATR unit. The fluorescence measurements 
were carried out on a Fluoromax 4 (Horiba) 
spectrofluorimeter, the UV-VIS measurements on a 
Cary 100 (Varian) spectrophotometer. 
 
6-cyano-N,N-diethylnicotinamide (5)20 
To a solution of 6-cyanonicotinic acid (250 mg, 1.6 
mmol) in THF (15 ml) were added HBTU (599 mg, 1.5 
mmol), HOBt (257 mg, 1.6 mmol), DIPEA (604 µl, 3.5 
mmol) and diethylamine (210 µl, 2.0 mmol). The 
resulting suspension was stirred at room temperature 
for 12 hours. After then, the volatiles were evaporated 
in vacuo. Purification of the product by column 
chromatography on silica gel with hexanes/EtOAc 3:1 
v/v afforded 5 as a pale yellow oil in 87% yield. 
1HNMR (CDCl3): δ= 8.66 (1H, d, J=1.2), 7.8 (1H, dd, 
J=7.9, 2.1), 7.7 (1H, dd, J=7.9, 0.7), 3.57-3.09 (4H, m), 
1.20 (6H, m). 
13CNMR (CDCl3): δ= 171.8, 147.2, 138.2, 131.8, 
131.3, 123.2, 116.2, 41.9, 13.15. 
 
N,N-diethyl-6-(1,2,4,5-tetrazin-3-yl)nicotinamide (1) 
Formamidine acetate (2.95 g, 28.32 mmol, 12 eq.) was 
dissolved in hydrazine monohydrate (aqueous 64%, 
10 mL) and heated to 60 °C. A solution of 5 (0.48 g, 
2.36 mmol, 1 eq.) in anhydrous ethanol (20 mL) was 
added dropwise (15 min) to it and the reaction mixture 
was stirred overnight at 80 °C. After evaporation of the 
solvent the remaining sticky residue was dissolved in 
EtOAc (200 mL), washed with 10 m/m% citric-acid 
solution (2×50 mL), cc. NaHCO3 solution (2×40 mL) 
and brine (30 mL) and dried over MgSO4. The solution 
was filtered and the solvent was removed in vacuo to 
furnish crude dihydrotetrazine, which was dissolved in 
CH2Cl2 (150 mL). Isopentyl nitrite (950 μL, 7.08 
mmol, 3 eq.) was added to the solution and the reaction 
mixture was stirred at room temperature for 3 h while 
the yellow solution turned deep red and TLC indicated 
the full consumption of the dihydrotetrazine. After 
evaporation of the solvent the crude product was 
purified by column chromatography (SiO2, 
CH2Cl2/MeOH = 50/1 → 30/1) to yield 256 mg 1 
(42%) as a purple-red solid. 
T.l.c.: Rf = 0.4 (CH2Cl2/MeOH = 94/6 v/v). 
M.p. = 222-225 °C (decomp.). 
1H NMR (250 MHz, CDCl3) δ = 10.35 (s, 1H), 8.91 (d, 
J = 1.8 Hz, 1H), 8.70 (d, J = 8.1 Hz, 1H), 7.99 (dd, J = 
8.1, 1.8 Hz, 1H), 3.56 (q, J = 6.5 Hz, 2H), 3.27 (q, J = 
6.5 Hz, 2H), 1.25 (t, J = 6.5 Hz, 3H), 1.14 (t, J = 6.5 Hz, 
3H). 
13C NMR (62.5 MHz, CDCl3) δ = 167.4, 165.2, 158.3, 
150.1 148.2, 135.8, 135.6, 123.9, 43.4, 39.6, 14.2, 12.7.  
IR (neat): νmax = 3074, 2936, 1618, 1429, 1344, 1096, 
866. 
HRMS (ESI) [M+H]+ calcd. for C12H15N6O+: 
259.1302, found: unable to acquire, decomposes. 
 
N,N-diethyl-6-(6-methyl-1,2,4,5-tetrazine-3-yl)-
nicotinamide (2) 
5 (420 mg, 2.0 mmol) was dissolved in MeCN (20 ml). 
Hydrazine monohydrate (aqueous 64%, 511 μl, 10.25 
mmol) was added to it dropwise and the solution was 
stirred at 90 °C for 12 hours. The volatiles were 
evaporated and the residue was dissolved in CH2Cl2. 
The solution was washed twice with citric acid solution 
(20 mL, 5% aqueous solution) and saturated Na2CO3 
(20 mL). The organic phase was dried over MgSO4, and 
filtered. Nitrous gases were bubbled through the 
solution for 10 minutes during which time the color of 
the solution turned deep pink. The solvent was 
evaporated and the crude product was purified by 
column chromatography on silica gel (CH2Cl2/MeOH 
30:1 v/v). Further purification by recrystallization from 
ethanol yielded 2 as bright magenta crystals (9%). 
Melting point: 177-179 °C (decomp.). 
T.l.c.: Rf = 0.3 (CH2Cl2/MeOH 30:1 v/v). 
1HNMR (400 MHz, CD3OD) δ = 8.85 (s, 1H), 8.75 (d, 
J = 7.8 Hz, 1H), 8.16 (d, J = 7.8 Hz, 1H), 3.62 (q, J = 
6.4 Hz, 2H), 3.38 (q, J = 6.4 Hz, 2H), 3.13 (s, 3H), 1.30 
(t, J = 6.4 Hz, 3H), 1.20 (t, J = 6.4 Hz, 3H) 
13CNMR (100 MHz, CD3OD) δ = 169.9, 169.8, 164.1, 
152.1, 148.8, 137.3, 136.7, 124.9, 45.1, 41.2, 21.3, 
14.4, 13.1. 
 170.3, 170.1, 164.6, 149.3, 137.8, 137.2, 125.3, 41.8, 
22.0, 13.6 ppm.  
IR (neat): υmax = 2979, 2967, 1617, 1403, 1363, 1285, 
867 cm-1. 
13CDEPT NMR (100 MHz, CDCl3): δ = 169.9(-), 
169.8(-), 164.1(-), 152.1(-), 148.8(+), 137.3(+), 136.7(-
), 124.9(+), 45.1(-), 41.2(-), 21.3(+), 14.4(+), 13.1(+). 
HRMS (ESI) [M+Na]+ calcd. for C13H16N6ONa+ : 
295.1283, found: 295.1295. 
 
6,6’-(1,2,4,5-tetrazine)-bis(N,N-diethylnicotinamide) 
(3) 
5 (297 mg, 1.4 mmol) was dissolved in 10 ml THF. 
Aqueous hydrazine monohydrate (64%, 141 µl, 2.93 
mmol) was added dropwise and the solution was stirred 
at 80 °C overnight. The THF was evaporated and the 
resulting crude dihydrotetrazine was redissolved in 150 
ml of CH2Cl2 and oxidized directly with nitrous gases. 
The nitrous gases were bubbled through the stirred 
solution for 10 minutes. After evaporation of CH2Cl2 
the crude product was purified by column 
chromatography on silica gel (CH2Cl2/MeOH 
94:6 v/v). Further purification is possible by 
recrystallization from EtOAc to yield 3 as magenta 
crystals (30%).  
T.l.c.: Rf = 0.7 (CH2Cl2/MeOH 94:6 v/v). 
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M.p.: 180-183 ⁰C (decomp.). 
1HNMR (400 MHz, CDCl3): δ = 8.98 (d, J = 1.4 Hz, 
2H), 8.81 (d, J = 8.2 Hz, 2H), 8.04 (dd, J = 8.2, 1.4 Hz, 
2H), 3.61 (q, J = 6.3 Hz, 4H), 3.33 (q, J = 6.3 Hz, 4H), 
1.40-1.10 (m, 12H). 
13CNMR (100 MHz, CDCl3): δ = 167.7, 163.6, 150.4, 
148.6, 136.0, 135.8, 124.5, 43.6, 39.9, 14.5, 13.0. 
IR (neat): υmax = 1629, 1427, 1362, 1290, 1124, 857, 
603 cm-1.  
13CDEPT NMR (100 MHz, CDCl3): δ = 167.7(-), 
163.6(-), 150.4(-), 148.6(+), 136.0(+), 135.8(-), 
124.5(+), 43.6(-), 39.9(-), 14.5(+), 13.0(+). 
HRMS (ESI) [M+Na]+ calcd. for C22H26N8O2Na+ : 
457.2076, found: 457.2092. 
 
6-(6-methyl-1,2,4,5-tetrazin-3-yl)nicotinic acid (6) 
6-cyanonicotinic acid (593 mg, 4.00 mmol, 1 eq.), 
sulfur (90 mg, 2.80 mmol, 0.7 eq.) and triethyl 
orthoacetate (18.3 mL, 100 mmol, 25 eq.) was placed 
in a round bottomed flask and flushed with N2. 
Hydrazine monohydrate (15 mL, 300 mmol, 75 eq.) 
was added and the reaction mixture was stirred 
vigorously at 100 °C for 2 h. After cooling to room 
temperature the solution was diluted with EtOAc (200 
mL) and washed with 10 m/m% citric-acid solution 
(2×75 mL), cc. NaHCO3 solution (2×50 mL), brine 
(30 mL) and dried over MgSO4. The solution was 
filtered and the solvent was evaporated. Crude 
dihydrotetrazine was suspended in CH2Cl2 (150 mL) 
and oxidized with in situ generated nitrous gases (NOx) 
till t.l.c. indicated the consumption of all 
dihydrotetrazine and the solution turned deep red. After 
evaporation of the solvent the crude product was 
purified by column chromatography (SiO2, 
CH2Cl2/MeOH = 9/1 v/v) to yield 218 mg 6 (25%) as a 
purple-red solid.  
T.l.c.: Rf = 0.2 (CH2Cl2/MeOH = 10/1 v/v). 
M.p. = 158-161 °C (decomp.).  
1HNMR (250 MHz, DMSO-d6) δ = 9.33 (dd, J = 2.1, 
0.7 Hz, 1H), 8.64 (dd, J = 8.2, 0.7 Hz, 1H), 8.56 (dd, J 
= 8.2, 2.1 Hz, 1H), 3.06 (s, 3H).  
13CNMR (150 MHz, DMSO-d6) δ = 167.7, 165.9, 
162.7, 153.2, 150.8, 138.5, 128.6, 123.7, 21.0.  
MS (ESI): [M-H]- calcd. for C9H6N5O2-: 216.1, found: 
216.0.  
IR(neat): νmax = 3051, 2850, 2552, 1680, 1402, 1247, 
1020. 
HRMS (ESI) [M+Na]+ calcd. for C9H7N5O2Na+: 
240,0492, found: 240.0484. 
 
N-(3-(1-((2R,4S,5R)-5-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-4-
hydroxytetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-
tetrahydropyrimidin-5-yl)prop-2-yn-1-yl)-6-(6-methyl-
1,2,4,5-tetrazin-3-yl)nicotinamide (7) 
In a round bottom flask 6 (56 mg, 0.26 mmol, 1 eq) 
HBTU (107 mg, 0.28 mmol, 1.1 eq) and HOBt (3.94 
mg, 0.03 mmol, 0.1 eq) were dried in vacuuo 
overnight. In a separate flask DMT-protected 
propargylamino modified deoxyuridine (150 mg, 
0.26 mmol, 1 eq) was also dried overnight in vacuo. 
The mixture of 6, HBTU and HOBt was dissolved in 
5 mL of dry DMF and was stirred for 15 min. 
Subsequently 60 µL DIPEA 0.35 mmol, 1.35 eq) were 
added and the solution was stirred for another 15 min. 
The DMT-protected propargylamino-deoxyuridine was 
also dissolved in 2 mL of dry DMF and added to the 
first solution, and the resulting mixture was stirred 
overnight at room temperature. The solvent was 
removed under reduced pressure at 40 °C and the 
residue was purified by column chromatography (SiO2, 
CH2Cl2/MeOH 30/1v/v +0.1% DIPEA) to furnish 7 in 
65% yield.  
T.l.c.: Rf = 0.3 (CH2Cl2/MeOH 15/1 v/v). 
1HNMR (300 MHz, DMSO-d6): δ = 11.70 (1H, s), 9.38 
(1H, t, J = 5.0), 9.28 (1H, m), 8.61 (1H, d, J = 8.2), 8.49 
(1H, d, J = 8.2), 7.94 (1H, s), 7.30 (9H, m), 6.89 (4H, 
m), 6.10 (1H, t, J = 6.3), 5.34 (1H, d, J = 4.4), 4.27 (1H, 
m), 4.22 (2H, d, J = 5.5), 3.92 (1H, m), 3.72 (6H, s), 
3.25 (2H, m), 3.06 (3H, s), 2.25 (2H, m). 
13C-NMR (100 MHz, DMSO-d6) = 167.75, 163.9, 
162.9, 161.7, 158.1, 152.35, 149.4, 149.3, 144.8, 143.5, 
136.85, 135.7, 135.2, 131.2, 129.8, 129.7, 128.4, 127.0, 
128.58, 123.45, 113.3, 98.3, 89.1, 85.9, 85.1, 74.5, 
70.5, 63.8, 55.1, 53.6, 45.8, 41.9, 29.5, 21.1, 18.1, 16.8, 
12.6, 8.7. 
HRMS  (ESI) [M+H]+ calcd. for: C42H39N8O8+: 
783.2884, found: 783.2885. 
 
(2R,3S,5R)-2-((bis(4-
methoxyphenyl)(phenyl)methoxy)methyl)-5-(5-(3-(6-
(6-methyl-1,2,4,5-tetrazin-3-yl)nicotinamido)prop-1-
yn-1-yl)-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-
yl)tetrahydrofuran-3-yl (2-cyanoethyl) 
diisopropylphosphoramidite (8) 
In a round bottom flask under argon atmosphere 80 mg 
7 (80 mg, 102 µmol, 1 eq) was dissolved in 2 mL abs. 
CH2Cl2 and 36.7 µL DIPEA (200 µmol, 2 eq) was 
added. To this solution 2-cyanoethyl-N,N-
diisopropylchloro phosphoramidite (34.2 µL, 
153 µmol, 1.5 eq) was added and the reaction was 
stirred for 1.5 h at room temperature. The reaction 
mixture was directly taken onto the chromatography 
column to elute the product very fast (SiO2, 
CH2Cl2/Aceton 3/2 v/v + 0.1% DIPEA). Evaporation 
of the solvent in vacuo and the resulting pink solid was 
lyophilized with benzene to obtain 8 in 89% yield.  
T.l.c.: Rf = 0.8 (CH2Cl2/Acetone 3/2 v/v). 
31PNMR (101 MHz, DMSO-d6); δ = 150.07, 149.67. 
HRMS (ESI) [M+H]+ calcd. for: C51H56N10O9P+: 
983.3964 found: 983.3962. 
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